Murat Toruner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Murat Toruner has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Irfan Soykan
Department of Gastroenterology, Faculty of Medicine, Ankara University, Ankara, Türkiye
3 shared publications Ali Ozden
2 shared publicationsAli Özden
Departments of Gastroenterology
2 shared publications- Gokhan Kabacam
Department of Gastroenterology, Guven Hospital, Ankara, Turkey
2 shared publications Hulya Cetinkaya
2 shared publications- Mehmet Bektaş
Department of Gastroenterology, Ankara University School of Medicine, Tip Fakultesi Hastanesi, Dikimevi, 06100 Ankara, Turkey
2 shared publications
Latest Publications
- 12 October 2011
- Published by Update Medical Publishing in Hepatogastroenterology
- Vol. 58 (112) , 1989-92
The Effect of Endogenous Hypergastrinemia on Lower Esophageal Sphincter Pressure and Esophageal Motility
The effect of exogenous hypergastrinemia on esophageal motor function has been well documented. However, it is not known whether chronic endogenous hypergastrinemia influences esophageal motility and lower esophageal sphincter pressure. The purpose of this study was to investigate the effect of chronic hypergastrinemia on lower esophageal sphincter pressure and esophageal motility in patients with significantly elevated serum gastrin levels. 37 patients (28 women; mean age, 53.7 years) with autoimmune gastritis and 35 functional dyspepsia patients participated in this study. Esophageal motility testing was performed by using an eight-lumen water-perfused catheter. Ten wet swallows were given and each contraction was analysed for lower esophageal sphincter pressure, lower esophageal sphincter relaxation, contraction amplitude and peak velocity. Mean serum fasting gastrin level was 1382.8±731.9pg/mL in patients with autoimmune gastritis and 107±83.9pg/mL in the control group (p=0.000). Mean lower esophageal sphincter pressure (31.6±14.42mmHg vs. 20.5±8.05mmHg, p=0.000) and mean contraction amplitude (82.48±35.0mmHg vs. 58.11±21.75mmHg, p=0.001), in hypergastrinemic patients were significantly higher than in the control group. These results suggest that in patients with autoimmune gastritis, prolonged and significant elevation of serum gastrin levels, increases lower esophageal sphincter pressure and esophageal body contraction amplitude. However, this increase in lower esophageal sphincter pressure does not cause upper gastrointestinal symptoms in patients with autoimmune gastritis.
- 12 October 2011
- Published by Update Medical Publishing in Hepatogastroenterology
- Vol. 58 (112) , 1989-92
The Effect of Endogenous Hypergastrinemia on Lower Esophageal Sphincter Pressure and Esophageal Motility
The effect of exogenous hypergastrinemia on esophageal motor function has been well documented. However, it is not known whether chronic endogenous hypergastrinemia influences esophageal motility and lower esophageal sphincter pressure. The purpose of this study was to investigate the effect of chronic hypergastrinemia on lower esophageal sphincter pressure and esophageal motility in patients with significantly elevated serum gastrin levels. 37 patients (28 women; mean age, 53.7 years) with autoimmune gastritis and 35 functional dyspepsia patients participated in this study. Esophageal motility testing was performed by using an eight-lumen water-perfused catheter. Ten wet swallows were given and each contraction was analysed for lower esophageal sphincter pressure, lower esophageal sphincter relaxation, contraction amplitude and peak velocity. Mean serum fasting gastrin level was 1382.8±731.9pg/mL in patients with autoimmune gastritis and 107±83.9pg/mL in the control group (p=0.000). Mean lower esophageal sphincter pressure (31.6±14.42mmHg vs. 20.5±8.05mmHg, p=0.000) and mean contraction amplitude (82.48±35.0mmHg vs. 58.11±21.75mmHg, p=0.001), in hypergastrinemic patients were significantly higher than in the control group. These results suggest that in patients with autoimmune gastritis, prolonged and significant elevation of serum gastrin levels, increases lower esophageal sphincter pressure and esophageal body contraction amplitude. However, this increase in lower esophageal sphincter pressure does not cause upper gastrointestinal symptoms in patients with autoimmune gastritis.
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5)
T1036 Clinical and Laboratory Features of Patients with Significantly Elevated Serum Gastrin Level
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5)
T1036 Clinical and Laboratory Features of Patients with Significantly Elevated Serum Gastrin Level
- 1 September 2008
- Vol. 19 (3) , 168-73
Effects of polymorphism in G2677T/A triallelic region of MDR1 gene in Turkish patients with inflammatory bowel disease.
Crohn's disease and ulcerative colitis are both chronic inflammatory disorders of the gastrointestinal tract, the main causes of which remain unknown. Crohn's disease and ulcerative colitis are characterized by cell-mediated immune response against the luminal bacteria. It is suggested that expression levels and function of P-glycoprotein, encoded by the MDR1 gene, are important for protection of the gut against xenobiotics and bacterial toxins. Therefore, the mutations of the MDR1 gene are thought to be related with the pathogenesis of inflammatory bowel disease. The aim of this study was to investigate the G2677T/A polymorphism in the MDR1 gene in Turkish patients with inflammatory bowel disease and a healthy control group. In our study, the genotypes of endoscopically or histopathologically diagnosed Crohn's disease (n: 35; 14 F, 21 M) and ulcerative colitis (n: 82; 36 F, 46 M) patients and of 70 healthy individuals (39 F, 31 M) were compared. In the patient and control groups, polymerase chain reaction restriction fragment length polymorphism analysis was performed for two polymorphisms (G2677T and G2677A) of the MDR1 gene. In this study, the frequency of alleles at position 2677 of the MDR1 gene, which has a triallelic polymorphism, was not found to be significantly different between the patient and the healthy control groups. Moreover, the 2677A allele was not detected in either the patient group or the healthy control group. In this study, the G2677T/A polymorphism observed in the MDR1 gene was not found to be a risk factor for Crohn's disease or ulcerative colitis.
- 1 September 2008
- Vol. 19 (3) , 168-73
Effects of polymorphism in G2677T/A triallelic region of MDR1 gene in Turkish patients with inflammatory bowel disease.
Crohn's disease and ulcerative colitis are both chronic inflammatory disorders of the gastrointestinal tract, the main causes of which remain unknown. Crohn's disease and ulcerative colitis are characterized by cell-mediated immune response against the luminal bacteria. It is suggested that expression levels and function of P-glycoprotein, encoded by the MDR1 gene, are important for protection of the gut against xenobiotics and bacterial toxins. Therefore, the mutations of the MDR1 gene are thought to be related with the pathogenesis of inflammatory bowel disease. The aim of this study was to investigate the G2677T/A polymorphism in the MDR1 gene in Turkish patients with inflammatory bowel disease and a healthy control group. In our study, the genotypes of endoscopically or histopathologically diagnosed Crohn's disease (n: 35; 14 F, 21 M) and ulcerative colitis (n: 82; 36 F, 46 M) patients and of 70 healthy individuals (39 F, 31 M) were compared. In the patient and control groups, polymerase chain reaction restriction fragment length polymorphism analysis was performed for two polymorphisms (G2677T and G2677A) of the MDR1 gene. In this study, the frequency of alleles at position 2677 of the MDR1 gene, which has a triallelic polymorphism, was not found to be significantly different between the patient and the healthy control groups. Moreover, the 2677A allele was not detected in either the patient group or the healthy control group. In this study, the G2677T/A polymorphism observed in the MDR1 gene was not found to be a risk factor for Crohn's disease or ulcerative colitis.
- 13 April 2004
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 19 (5) , 535-540
Barrett's esophagus: Prevalence and its relationship with dyspeptic symptoms
Background and Aim: Barrett's metaplasia is a premalign condition which plays a pivotal role in the development of esophageal adenocarcinoma. It is considered a complication of chronic gastroesophageal reflux disease. Although esophageal adenocarcinoma is an uncommon cancer, its incidence is rapidly increasing. The aims of the present study were to determine the prevalence of Barrett's metaplasia in outpatients referred for gastroscopy for upper gastrointestinal symptoms, and to clarify the relationship between Barrett's metaplasia and upper gastrointestinal symptoms.Methods: Three‐hundred and ninety‐five consecutive dyspeptic patients, never previously investigated, underwent gastroscopy and were enrolled into the study.Results: Barrett's metaplasia was detected in 29 patients (7.4%). The age‐specific prevalence of Barrett's metaplasia increased with age. In multivariate analysis, Barrett's metaplasia was independently and positively related to age, sex and duration of symptoms, but not with upper gastrointestinal symptoms. In univariate analysis, Barrett's metaplasia was significantly more common in patients with antral intestinal metaplasia (24%) and presence of hiatal hernia (65.5%), compared with those with normal endoscopic findings (6.2% and 39.2%, respectively, p = 0.001).Conclusion: Symptoms do not predict Barrett's metaplasia. Barrett's metaplasia is age‐related and more common in patients with a longer duration of symptoms, presence of hiatal hernia and antral intestinal metaplasia.
- 13 April 2004
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 19 (5) , 535-540
Barrett's esophagus: Prevalence and its relationship with dyspeptic symptoms
Background and Aim: Barrett's metaplasia is a premalign condition which plays a pivotal role in the development of esophageal adenocarcinoma. It is considered a complication of chronic gastroesophageal reflux disease. Although esophageal adenocarcinoma is an uncommon cancer, its incidence is rapidly increasing. The aims of the present study were to determine the prevalence of Barrett's metaplasia in outpatients referred for gastroscopy for upper gastrointestinal symptoms, and to clarify the relationship between Barrett's metaplasia and upper gastrointestinal symptoms.Methods: Three‐hundred and ninety‐five consecutive dyspeptic patients, never previously investigated, underwent gastroscopy and were enrolled into the study.Results: Barrett's metaplasia was detected in 29 patients (7.4%). The age‐specific prevalence of Barrett's metaplasia increased with age. In multivariate analysis, Barrett's metaplasia was independently and positively related to age, sex and duration of symptoms, but not with upper gastrointestinal symptoms. In univariate analysis, Barrett's metaplasia was significantly more common in patients with antral intestinal metaplasia (24%) and presence of hiatal hernia (65.5%), compared with those with normal endoscopic findings (6.2% and 39.2%, respectively, p = 0.001).Conclusion: Symptoms do not predict Barrett's metaplasia. Barrett's metaplasia is age‐related and more common in patients with a longer duration of symptoms, presence of hiatal hernia and antral intestinal metaplasia.
- 30 April 2003
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , A182
The effect of saccharomyces boulardii on gastrointestinal symptoms and helicobacter pylori eradication in patients with functional dyspepsia
- 30 April 2003
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , A182
The effect of saccharomyces boulardii on gastrointestinal symptoms and helicobacter pylori eradication in patients with functional dyspepsia
- 1 April 2002
- Published by Turkish Journal of Academic Gastroenterology in Akademik Gastroenteroloji Dergisi
- Vol. 1 (1)
Akalazya-Bir olgu sunumu nedeniyle
- 1 April 2002
- Published by Turkish Journal of Academic Gastroenterology in Akademik Gastroenteroloji Dergisi
- Vol. 1 (1)
Akalazya-Bir olgu sunumu nedeniyle